It has been a wild ride for some of the UK's biggest quoted companies over the past year. Economic uncertainty persists and the question on the minds of many investors is where the prices of stocks like Dechra Pharmaceuticals (LON:DPH)...
DPH — Dechra Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00HealthcareBalancedLarge CapFalling Star
- £3.74bn
- £3.93bn
- £608.00m
- 95
- 12
- 43
- 46
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 27.32 | ||
| PEG Ratio (f) | 2.29 | ||
| EPS Growth (f) | 13.57% | ||
| Dividend Yield (f) | 1.37% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.85 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 73.47 | ||
| Price to Sales | 5.84 | ||
| EV to EBITDA | 20.5 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 9.74% | ||
| Return on Equity | 11.53% | ||
| Operating Margin | 15.94% | ||
Financial Summary
| Year End 30th Jun | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 359.27 | 407.1 | 481.8 | 515.1 | 608 | 664.13 | 717.11 | 19.69% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +153.74 | +24.18 | -7.43 | -2.15 | +10.23 | +81.15 | +8.98 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health Trend(F-Score)
12345678910
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Latest News & Insights for DPH
It has been a wild ride for some of the UK's biggest quoted companies over the past year. Economic uncertainty persists and the question on the minds of many investors is where the prices of stocks like Dechra Pharmaceuticals (LON:DPH)...
While the world continues to wrestle with the consequences of the Covid-19 pandemic, investors are naturally wondering what lies in store for some of the country's largest quoted companies, such as Dechra Pharmaceuticals (LON:DPH). De...
While the world continues to wrestle with the consequences of the Covid-19 pandemic, investors are naturally wondering what lies in store for some of the country's largest quoted companies, such as Dechra Pharmaceuticals (LON:DPH). De...
While the world continues to wrestle with the consequences of the Covid-19 pandemic, investors are naturally wondering what lies in store for some of the country's largest quoted companies, such as Dechra Pharmaceuticals (LON:DPH). De...
Profile Summary
Dechra Pharmaceuticals PLC is engaged in veterinary pharmaceuticals and related products business. The Company is engaged in development, manufacture and marketing of products for veterinarians. Its segments include European Pharmaceuticals, North American (NA) Pharmaceuticals and Pharmaceuticals Research and Development. The European Pharmaceuticals Segment includes Dechra Veterinary Products Europe, Dechra Veterinary Products International and Dechra Pharmaceuticals Manufacturing. It manufactures and markets companion animal, equine, food producing animal products and nutrition. The North American (NA) Pharmaceuticals segment consists of Dechra Veterinary Products US, Dechra Produtas Veterinarios (Mexico) and Dechra Veterinary Products Canada, which sells companion animal, equine and food producing animal products. The segment also includes its manufacturing units based in Melbourne, Florida and Fort Worth, Texas.
Directors
- Alison Platt CHM
- Ian Page CEO
- Paul Sandland CFO
- Mike Eldred CEX
- Anthony Griffin MDR
- Katy Clough DHR
- Giles Coley OTH (59)
- Anthony Lucas OTH
- Milton McCann OTH
- Allen Mellor OTH
- Melanie Hall SEC
- Lisa Bright NID (53)
- Julian Heslop NID (66)
- Lawson Macartney NID (63)
- Ishbel Macpherson NID (60)
- Last Annual
- June 30th, 2021
- Last Interim
- December 31st, 2021
- Incorporated
- May 13th, 1997
- Public Since
- September 21st, 2000
- No. of Employees
- 1,945
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 108,389,445
- Address
- 24 Cheshire Avenue, NORTHWICH, CW9 7UA
- Web
- https://www.dechra.com/
- Phone
- +44 1606814730
- Contact
- Ian Page
- Auditors
- PricewaterhouseCoopers LLP
Latest News for DPH
Upcoming Events for DPH
Full Year 2022 Dechra Pharmaceuticals PLC Earnings Release
Dechra Pharmaceuticals PLC Annual Shareholders Meeting
Similar to DPH
Abcam
London Stock Exchange
Alliance Pharma
London Stock Exchange
Animalcare
London Stock Exchange
AstraZeneca
London Stock Exchange
Benchmark Holdings
London Stock Exchange
FAQ
What is the Dechra Pharmaceuticals share price?
As of Today at 07:06 UTC, shares in Dechra Pharmaceuticals are trading at 3,450.00p. This share price information is delayed by 15 minutes.
How has the Dechra Pharmaceuticals share price performed this year?
Shares in Dechra Pharmaceuticals last closed at 3,450.00p and the price had moved by -14.65% over the past 365 days. In terms of relative price strength the Dechra Pharmaceuticals share price has underperformed the FTSE All Share Index by -16.34% over the past year.
What are the analyst and broker recommendations for Dechra Pharmaceuticals?
The overall consensus recommendation for Dechra Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Dechra Pharmaceuticals dividend yield?
The Dechra Pharmaceuticals dividend yield is 1.2% based on the trailing twelve month period.
Does Dechra Pharmaceuticals pay a dividend?
Last year, Dechra Pharmaceuticals paid a total dividend of £0.41, and it currently has a trailing dividend yield of 1.2%. We do not have any data on when Dechra Pharmaceuticals is to next pay dividends.
When does Dechra Pharmaceuticals next pay dividends?
We do not have data on when Dechra Pharmaceuticals is to next pay dividends. The historic dividend yield on Dechra Pharmaceuticals shares is currently 1.2%.
How do I buy Dechra Pharmaceuticals shares?
To buy shares in Dechra Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Dechra Pharmaceuticals?
As of the previous close price of 3,450.00p, shares in Dechra Pharmaceuticals had a market capitalisation of £3.74bn.
Where are Dechra Pharmaceuticals shares listed?
Here are the trading details for Dechra Pharmaceuticals:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: DPH
What kind of share is Dechra Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Dechra Pharmaceuticals is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Dechra Pharmaceuticals share price forecast for 2022?
The analyst consensus target price for shares in Dechra Pharmaceuticals is 4,842.70p. That is 40.37% above the last closing price of 3,450.00p.
Analysts covering Dechra Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of £1.17 for the next financial year.
What is the trend in the Dechra Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Dechra Pharmaceuticals. Over the past six months, its share price has underperformed the FTSE All Share Index by -34.69%.
As of the last closing price of 3,450.00p, shares in Dechra Pharmaceuticals were trading -23.61% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Dechra Pharmaceuticals PE Ratio?
The Dechra Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 27.32. The shares last closed at 3,450.00p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Dechra Pharmaceuticals?
Dechra Pharmaceuticals' management team is headed by:
- Alison Platt - CHM
- Ian Page - CEO
- Paul Sandland - CFO
- Mike Eldred - CEX
- Anthony Griffin - MDR
- Katy Clough - DHR
- Giles Coley - OTH
- Anthony Lucas - OTH
- Milton McCann - OTH
- Allen Mellor - OTH
- Melanie Hall - SEC
- Lisa Bright - NID
- Julian Heslop - NID
- Lawson Macartney - NID
- Ishbel Macpherson - NID